Studies indicated that PCa patients have 4-fold higher levels of nanovesicles expressing both PSA and CD81 (exosomal marker) compared to benign prostate hypertrophy (BPH) patients and healthy individuals where TME acidity seems to regulate the release of PSA-EVs in the blood of PCa patients (79). Here, CD81 is linked to benign prostatic hyperplasia.